EGFR (a dimer of HER-1 and HER-2) and VEGFR-2 (KDR, a type of VEGFRs) are pro-angiogenic growth factor receptors that induce angiogenesis process in order to establish new blood vessels that have an important role in tumor growth and metastasis; therefore, they are attractive therapy targets and dominant strategy for the treatment of cancer [1–6]. The gene discussed is EGFR; the disease is cancer.